Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20338965 | 0.88 | PAICS (0.90) | PAICS | |
| SCHEMBL20338968 | 0.87 | PAICS (1.00) | PAICS | |
| SCHEMBL20351973 | 0.85 | PAICS (1.00) | PAICS | |
| SCHEMBL20350481 | 0.84 | PAICS (1.00) | PAICS | |
| SCHEMBL21571623 | 0.84 | PAICS (1.00) | PAICS | |
| SCHEMBL20338899 | 0.84 | PAICS (1.00) | PAICS | |
| SCHEMBL21571647 | 0.83 | PAICS (0.91) | PAICS | |
| SCHEMBL20338919 | 0.82 | PAICS (0.77) | PAICS | |
| SCHEMBL21571611 | 0.82 | PAICS (1.00) | PAICS | |
| SCHEMBL29395076 | 0.82 | PAICS (1.00) | PAICS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562825-B1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2022-02-16 | — | — | EP | disclosed |
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | LIFEARC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2019-11-21 | — | — | US | disclosed |
| EP-3562825-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LifeArc (GB) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122550-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122550-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | LIFEARC (GB) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961234-B2 | Oxazole derivatives for use in the treatment of cancer | PAICS, SMARCC2, OXA1L | PAICS 1/4885 |
| US-20190352296-A1 | OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | PAICS, SMARCC2, OXA1L | PAICS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.